Dry Age-Related Macular Degeneration Market Size in the 7MM was ~USD 1,300 Million in 2023, it is expected to grow by 2034, according to DelveInsight

The Dry AMD Market in the 7MM was valued at ~USD 1,300 Million in 2023, over the study period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Dry AMD Market Landscape. By analyzing historical data, current Dry AMD Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Dry AMD Market is increasingly guided by biomarker-driven strategies. Dry Age-Related Macular Degeneration (Dry AMD) is a chronic, progressive eye disorder that affects the macula — the central part of the retina responsible for sharp, detailed, and color vision. It is the most common form of AMD, accounting for about 85–90% of all cases.

DelveInsight’s report, “Dry AMD Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Dry AMD Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Dry AMD Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Dry AMD Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Dry AMD Market Forecast

Key Takeaways from Dry AMD Market Report

• The leading Dry AMD Companies, such as Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Regenerative Patch Technologies, and others.
• Promising Dry AMD Therapies such as Gildeuretinol (ALK-001), Tinlarebant (LBS-008), AVD-104, JNJ-1887, Luminate (risuteganib), OpRegen, CT1812, Elamipretide, ANX007 and others.
• The Dry AMD Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Dry AMD Pipeline products will significantly revolutionize the Dry AMD Market Dynamics.

Dry AMD Overview

 Dry AMD can be thought of as a gradual energy crisis inside the retina. Over time, the supporting cells beneath the macula — especially the retinal pigment epithelium (RPE) — begin to lose their ability to recycle visual proteins, clear metabolic waste, and nourish the light-sensing photoreceptors. As this cellular “maintenance system” weakens, toxic debris known as drusen starts to accumulate like clogged filters in an aging engine.

Get a Free sample for the Dry AMD Market Report @ https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market

Key Trends in the Dry AMD Market

• Rapid Growth Driven by Rising Prevalence of Geographic Atrophy (GA)

With aging populations globally, the incidence of Dry AMD—especially advanced GA—is increasing sharply. This growing patient pool is expanding the overall market size and attracting substantial investment from pharmaceutical companies.

• Surge in Complement Pathway–Targeted Therapies

Dry AMD drug development is increasingly focused on complement inhibitors (C3 and C5 blockers), reflecting the central role of complement dysregulation in disease progression. Multiple candidates are advancing through late-stage trials, making complement inhibition the dominant R&D theme in this space.

• Shift From Symptomatic Management to Disease-Modifying Treatments

Historically, Dry AMD management relied on supplements, lifestyle changes, and monitoring. Today’s pipeline is focused on slowing or altering disease progression, marking a major shift toward true disease-modifying therapies for the first time in this indication.

• Strong Momentum in Gene Therapy and Cell-Based Regeneration

Emerging approaches, including AAV gene therapies, RPE cell replacement, and stem cell–derived retinal implants, are gaining traction. These modalities aim to restore function rather than just slow decline, representing a future transformative trend in the market.

• Increased Focus on Early-Stage Disease Intervention

Companies are expanding beyond GA and targeting intermediate Dry AMD, aiming to intervene earlier, preserve more vision, and broaden the treatable population. Early-intervention therapies could significantly increase market potential.

• Advances in Imaging and AI-Driven Diagnostics

High-resolution OCT, fundus autofluorescence, and AI-based progression prediction tools are enabling earlier detection and more precise monitoring. These technologies will improve patient selection, accelerate clinical trials, and support personalized therapy strategies.

• Rising Demand for Real-World Evidence (RWE)

Regulators and payers increasingly require robust real-world data for Dry AMD therapies. This trend is fueling partnerships between industry, health systems, and digital health companies to gather large-scale real-world insights.

Dry AMD Epidemiology Segmentation in the 7MM

The Dry AMD Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total prevalent cases of AMD
• Stage-specific prevalent cases of AMD
• Total prevalent cases of geographic atrophy
• Total prevalent cases of dry AMD
• Total diagnosed prevalent cases of dry AMD
• Age-specific cases of early and intermediate AMD
• Age-specific cases of geographic atrophy
• Geographic atrophy cases by visual impairment

Download the report to understand which factors are driving Dry AMD Epidemiology trends @ Dry AMD Epidemiology Forecast

Recent Development in the Dry AMD Treatment Landscape

• On December 05, 2025- Ocugen announced a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 60 subjects.

Dry AMD Companies and Therapies

• Ocugen: OCU410
• Novartis Pharmaceuticals: LKA651
• Eyestem Research Pvt Ltd: Eyecyte-RPE
• Alcon Research: CLG561/LFG316
• Kubota Vision Inc.: ACU-4429

To know more about Dry AMD Companies working in the treatment market, visit @ Dry AMD Clinical Trials and Therapeutic Assessment

Dry AMD Market Drivers

• Rising Prevalence Driven by Aging Populations

The increasing number of elderly individuals across the US, Europe, and key Asian markets is a major catalyst for Dry AMD growth. As age remains the strongest risk factor, expanding geriatric demographics directly contribute to a larger patient pool, thereby driving market demand.

• Significant Unmet Need and Limited Approved Therapies

Dry AMD continues to face a substantial lack of effective treatment options, especially for early and intermediate stages. This unmet need fuels strong research interest and creates a high-value opportunity for novel therapeutics, encouraging robust industry participation and investment.

• Rapid Advancements in the Therapeutic Pipeline

A growing number of companies are actively developing innovative therapies for Dry AMD, including complement inhibitors, anti-inflammatory agents, neuroprotective strategies, cell-based approaches, and gene therapies. These advancements are expected to reshape the treatment landscape and accelerate market expansion.

• Improved Understanding of Disease Mechanisms

Deeper insights into the biological pathways underlying Dry AMD—such as complement activation, oxidative stress, and retinal degeneration—are enabling more targeted drug development. This scientific progress strengthens R&D confidence and supports the commercialization potential of emerging therapies.

• Enhanced Diagnostic Capabilities

Widespread adoption of high-resolution imaging technologies like OCT (Optical Coherence Tomography) and fundus autofluorescence has improved early detection and disease monitoring. Increased diagnostic accuracy leads to larger identified patient populations and supports better clinical management.

• Growing Awareness among Patients and Clinicians

Awareness campaigns, better access to eye-care services, and routine vision screenings are promoting earlier diagnosis and higher patient engagement. This growing disease awareness encourages proactive management and increases demand for therapeutic options.

Dry AMD Market Barriers

• Lack of Approved Disease-Modifying Therapies

Dry Age-Related Macular Degeneration still has no widely approved disease-modifying treatment, unlike wet AMD. Most available options focus on slowing progression rather than reversing damage. This limited therapeutic landscape significantly restricts market growth and lowers adoption potential.

• Complex and Incomplete Understanding of Pathophysiology

The multifactorial nature of Dry AMD—driven by genetics, oxidative stress, inflammation, and aging—creates scientific complexity. This incomplete understanding of disease biology continues to slow R&D success and causes high late-stage attrition.

• High Clinical Trial Failure Rates

Numerous investigational therapies targeting complement pathways, oxidative stress, and inflammation have failed to meet endpoints. These frequent trial failures create investor hesitation, increase development costs, and limit pipeline momentum.

• Slow and Heterogeneous Disease Progression

Dry AMD progresses gradually and varies widely between individuals. This makes patient recruitment, trial design, and endpoint measurement extremely challenging. Long study durations add high costs and delay approvals.

• Difficulty in Identifying Robust Biomarkers

The market suffers due to limited validated biomarkers that can reliably track disease progression or therapeutic response. Without strong surrogate endpoints, regulators demand longer, larger trials.

• Limited Awareness and Late Diagnosis

Many early-stage Dry AMD cases go undiagnosed because symptoms are subtle. Low awareness among patients and delayed diagnosis reduce timely interventions and impact treatment uptake.

• High Cost of Advanced Diagnostics

Technologies like OCT angiography and advanced retinal imaging are expensive, especially in emerging markets. This limits broad adoption of screening and monitoring tools, slowing overall market expansion.

• Competition from Nutritional Supplements & Off-Label Options

Widespread use of AREDS/AREDS2 supplements often acts as a low-cost substitute for prescription treatments in early stages, reducing the willingness to adopt new, potentially expensive therapies.

• Regulatory Uncertainty

Regulators still debate optimal endpoints for Dry AMD, especially for GA (Geographic Atrophy) progression and visual function. This uncertainty complicates product approvals and discourages pipeline investment.

• High Unmet Need Leading to High Expectations

Patients and clinicians expect significant functional improvement, but most emerging therapies offer only slowed degeneration, not restoration. This expectation gap can affect adoption and satisfaction.

Scope of the Dry AMD Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Dry AMD Companies- Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Regenerative Patch Technologies, and others.
• Dry AMD Therapies- Gildeuretinol (ALK-001), Tinlarebant (LBS-008), AVD-104, JNJ-1887, Luminate (risuteganib), OpRegen, CT1812, Elamipretide, ANX007 and others.
• Dry AMD Therapeutic Assessment: Dry AMD current marketed and Dry AMD emerging therapies
• Dry AMD Market Dynamics: Dry AMD market drivers and Dry AMD market barriers
• Dry AMD Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Dry AMD Unmet Needs, KOL’s views, Analyst’s views, Dry AMD Market Access and Reimbursement

Discover more about therapies set to grab major Dry AMD Market Share @ Dry AMD Treatment Market

Table of Contents

1. Key Insights

2. Dry AMD Market Report Introduction

3. Dry AMD Market Overview at a Glance

4. Dry AMD Executive Summary

5. Key Events

6. Dry AMD Market Disease Background and Overview

7. Dry AMD Methodology

8. Dry AMD Population

9. Dry AMD Patient Journey

10. Dry AMD Marketed Drugs

11. Dry AMD Emerging Drugs

12. Dry AMD – 7MM Market Analysis

13. Dry AMD KOL Views

14. Dry AMD Unmet Needs

15. Dry AMD SWOT Analysis

16. Dry AMD Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.